President William Ruto has suspended Dr. Swarup Mishra from his position as Chairperson of the Kenya BioVax Institute, citing ongoing investigations into a high-profile organ trafficking scandal linked to Mediheal Hospital, a private healthcare chain founded by the former legislator.
The suspension, announced on April 18, 2025, follows mounting allegations surrounding unethical kidney transplant procedures conducted at Mediheal Hospital and Fertility Centre in Eldoret.
The Ministry of Health has since halted all kidney transplant operations at the hospital, pending the outcome of a full-scale audit.
Dr. Mishra, who was appointed to head BioVax in November 2024, has faced increased scrutiny following whistleblower accounts and investigative reports suggesting breaches of medical ethics, regulatory lapses, and potential exploitation of vulnerable patients in transplant cases.
BioVax, a state-owned firm tasked with developing and producing vaccines and other critical health products, now finds itself entangled in reputational risk amid the fallout.
In response, Health Cabinet Secretary Aden Duale constituted an independent committee to audit all kidney transplant procedures performed at Mediheal over the past five years.
The committee will examine clinical standards, governance protocols, and ethical compliance, with a report due within 90 days.
President Ruto underscored the government’s commitment to upholding ethical governance in the healthcare sector, emphasizing zero tolerance for misconduct—especially in institutions entrusted with public health and biotechnology innovation.
The suspension could also signal wider implications for private health investors and medical service providers operating in Kenya, as the government intensifies scrutiny of health sector practices.
It comes at a time when BioVax is positioned as a key pillar in Kenya’s biomedical and pharmaceutical self-reliance ambitions.
Dr. Mishra’s removal from BioVax leadership will likely trigger a leadership reshuffle and renewed calls for stronger oversight mechanisms across public-private health partnerships.
